Firm and Four Attorneys Again Recognized by LMG Life Sciences as Industry Leaders
Firm and Four Attorneys Again Recognized by LMG Life Sciences as Industry LeadersSeptember 25, 2019
The 2019 edition of LMG Life Sciences named E. Anthony Figg, Steven Lieberman, Joseph A. Hynds, and R. Danny Huntington as Life Sciences Stars in Intellectual Property and recommended the firm for Hatch-Waxman Patent Litigation (Generic). LMG Life Sciences is the definitive guide to leading North American law firms and lawyers specialized in the life sciences industry. The publication compiles the leading attorney and firm rankings based on case evidence, and client and peer feedback.
E. Anthony Figg was inducted into the LMG Life Sciences Hall of Fame in September 2018 for his remarkable achievements in the industry. He is recognized in the General Patent Litigation and Hatch-Waxman Patent Litigation practice areas in the 2019 rankings. Mr. Figg specializes in intellectual property law, primarily involving the chemical, pharmaceutical, health care, and biotechnology industries. His practice focuses on patent litigation and inter partes matters before the PTAB, appeals, ADR, patent procurement, intellectual property licensing and related contract matters, opinions, and counseling.
Steven Lieberman is recognized in the areas of General Patent Litigation, Hatch-Waxman Patent Litigation, and Patent Strategy & Management. He has been litigating patent and other intellectual property cases since 1991, and he has served as lead counsel in numerous lawsuits in the pharmaceutical, biotech, veterinary, and medical products fields, including handling more than 30 Hatch-Waxman litigations. Mr. Lieberman has experience representing both generic and brand name companies across district courts, the Federal Circuit, and the International Trade Commission. He also regularly advises clients on biosimilar issues and represents clients in IPR proceedings.
Joseph A. Hynds, recognized for Hatch-Waxman Patent Litigation, has been practicing across the full spectrum of IP law at the firm for over 25 years, with a focus on patent infringement litigation. Mr. Hynds has particular expertise in Hatch-Waxman litigation and related issues, having litigated numerous cases and in many, serving as lead counsel. He also has participated in numerous appeals to the U.S. Court of Appeals for the Federal Circuit. Mr. Hynds handles cases covering a broad range of pharmaceutical, medical device, biotechnology, and chemical technologies, among others.
Danny Huntington was presented as the Patent Strategy & Management Attorney of the Year in the District of Columbia for 2019 during the 7th Annual LMG Life Sciences Awards on September 18, 2019. The event was part of the 2019 research cycle for LMG Life Sciences. In the 2019 rankings, Mr. Huntington is recognized in the practice areas of General Patent Litigation, Patent Prosecution, and Patent Strategy & Management. Mr. Huntington is involved in all phases of intellectual property law, including U.S. and foreign patent prosecution, litigation in the federal and state courts, licensing, and general client counseling. He has extensive patent interference experience, with particular experience in biotechnology and pharmaceuticals.
Also at the LMG Life Sciences Awards held in September 2019, the firm was presented as a winner of a Hatch-Waxman Impact Case of the Year for its work representing Pfizer and Synthon in the Teva Pharmaceuticals et al v. Sandoz et al. (Fed. Circ. 2018) case.
To learn more about LMG Life Sciences, and to view the full firm and attorney rankings, please visit www.lmglifesciences.com.